The non-natural amino acids (R)-and (S)-2-amino-3-fluoro-2-methylpropanoic acid 5 and (R)-and (S)-3-fluoro-2-methyl-2-N-(methylamino)propanoic acid 8 were synthesized in shorter reaction sequences than in the original report starting from enantiomerically pure (S)-and (R)-α-methylserine, respectively. The reaction sequence provided the cyclic sulfamidate precursors for radiosynthesis of (R)-and (S)- 
Introduction
The development of radiotracers for tumor imaging is a major focus of radiopharmaceutical research. A number of classes of compounds that accumulate preferentially in neoplastic tissues have been investigated for this purpose, including metabolically based radiotracers such as carbohydrates, amino acids and nucleosides. The most widely used metabolic imaging agent for oncologic applications, 2-[ 18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG), has demonstrated clinical utility in staging, treatment planning and monitoring response to therapy for a number of types of cancers. 1, 2 While [ 18 F]FDG has proven very useful, this radiopharmaceutical does have some limitations for tumor imaging including high uptake in inflammatory tissue, low or variable uptake in certain neoplasm, and high physiological uptake in certain organs and tissues including the kidneys, urinary tract and normal gray matter of the brain. 3, 4 Amino acids are important biological substrates in virtually all biological process and are required nutrients for cell growth, [5] [6] [7] and many tumor cells demonstrate increased amino acid transport relative to normal tissues. 8, 9 Certain amino acid transporters also are involved in cell signaling and may play important roles in tumor biology. [10] [11] [12] A variety of radiolabeled amino acids have been developed as potential tumor imaging agents for positron emission tomography (PET) and single photon emission tomography (SPECT). Non-natural amino acids generally have higher metabolic stability than natural proteogenic amino acids, and this increased stability can simplify the interpretation of diagnostic images and kinetic analysis. A number of radiolabeled amino acids including tyrosine analogs O- (2- 21 These compounds are primarily A-type amino acid transporter substrates, and racemic mixtures of both [ 18 F]5 and [ 18 F]8 have demonstrated high tumor to brain ratios in the 9L gliosarcoma rat tumor model, in part as a result of low normal brain uptake due to the absence of A-type amino acid transport across the luminal surface of normal endothelium of the blood-brain barrier (BBB). 22 23 iodovinyl substituted analogues of AIB, demonstrated that the stereochemistry of IVAIB at the α-carbon strongly affects both in vitro and in vivo properties. In the 9L gliosarcoma model, (S)-[ 123 I]IVAIB, an A-type amino acid transporter substrate, demonstrated superior biological properties compared to the (R)-enantiomer. Based on the above observation and the promising results obtained with racemic 5 and 8, our goal was to improve the synthetic route and to evaluate the individual (S)-and (R)-enantiomers of 5 and 8 in the 9L gliosarcoma model to determine the effect of stereochemistry on the biological properties of these compounds.
Our recent comparisons of the in vitro and in vivo properties of (S)-and (R)-2-amino-2-methyl-4-[ 123 I]iodo-3-(E)-butenoic acid ([ 123 I]IVAIB),

Results and discussion
Chemistry
The non-radioactive amino acids (S)-and (R)-5 were prepared in a simple 5 step synthesis as shown in Scheme 1. This method is an improvement over the originally reported method which employed a Strecker-type reaction to prepare compound 5 as a racemic mixture. 22 Commercially available (S)-and (R)-α-methyl-serine were treated with di-tert-butyl dicarbonate to give carbamates (S)-and (R)-1 which were used without purification in the next reaction. Because of the presence of both carboxylic acid and hydroxy functionalities, protection of the carboxylic function as a tert-butyl ester without ether formation was necessary. The use of tertbutyl-2,2,2-trichloroacetimidate led to the formation of both the tert-butyl ester as well as the tert-butyl ether. In contrast, N,N-dimethylformamide di-tert-butyl acetal 24, 25 provided selective esterification of the carboxylic acid function when heated with (S)-or (R)-1 in anhydrous toluene.
The next key step for making the target radiolabeling precursors (S)-and (R)-4 was preparation of cyclic sulfamidites from 2. The typical approach of reacting the N-tert-butoxycarbonyl (Boc) protected amino alcohols (S)-and (R)-2 with thionyl chloride in the presence of triethylamine in low polarity solvent at low temperature failed to give the corresponding cyclic sulfamidites.
Our previous strategy was to replace the Boc group with the electron releasing group bis(4-methoxyphenyl)methyl, also known as 4,4′-dimethoxybenzhydryl (DMB) group. 22 While effective, this approach added at least two synthetic steps to the sequence and required the preparation of bis(4-methoxyphenyl)chloromethane 26 for N-alkylation. This problem with cyclization of the N-Boc compound was successfully solved by utilizing Posakony's method 27 which uses a more polar solvent for cyclization. The carbamate nitrogens of (S)-and (R)-2 are predicted to be less nucleophilic than their N-alkyl counterparts, and the use of acetonitrile allowed formation of the N-Boc protected cyclic sulfamidites (S)-and (R)-3. Further oxidation of 3 using sodium periodate with ruthenium (III) chloride catalysis provided the cyclic sulfamidates (S)-and (R)-4 which served as radiolabeling precursors for (R)-and (S)-[ 18 The preparation of (R)-and (S)-8 from the cyclic sulfamidate intermediates (S)-and (R)-4, respectively, required selective removal of the N-Boc group. Attempts to remove the N-Boc group in the presence of the tert-butyl ester using p-toluenesulfonic acid 22 or with anhydrous hydrochloric acid in dioxane 28 were not successful, presumably due to high sensitivity of the cyclic sulfamidate towards the acidic condition. Selective removal of the N-Boc group was achieved by treatment of 4 with methanesulfonic acid in tert-butyl acetate/dichloromethane as solvent. 29 The success of this reaction is likely because the removal of Boc group is an irreversible process due to protonation of the amine group and loss of CO 2 . In contrast, the acidic deprotection of the tert-butyl ester is a reversible process due to the nature of the tertbutyl carbonium ion mediated equilibrium with a tert-Bu + source. The likely reaction route is displayed in Scheme 2. The possible byproducts or intermediates 9 and 10 and their interchanging between 4 and 6 were observed by TLC at different reaction points. Using a mild organic acid such as methanesulfonic acid under anhydrous condition to prevent cyclic sulfamidate ring opening was the key to successfully prepare (S)-and (R)-6 from (S)-4 and (R)-4, respectively. The N-methylation of (S)-6 and (R)-6 was achieved by utilizing dimethyl sulfate with sodium hydride, 30 which provided (S)-7 and (R)-7 in good yields. Initial attempts using methyl iodide as the methylating agent for this reaction were unsuccessful.
Radiochemistry
The radiosyntheses of (R)-[ 18 F]fluoride using a modified automated method as previously described. 31 The cyclic sulfamidate precursors (S)-4 and (R)-4 provided an average 52 ± 12% of (R)-[ 18 F]5 (n= 10) and 56 ± 12% of (S)-[ 18 F] 5 (n= 6) decay corrected yields (DCY), respectively, in over 99% radiochemical purity based on radiometric TLC. Similarly, treatment of (S)-7 and (R)-7 under the same conditions gave an average 66 ± 12% of (R)-[ 18 F]8 (n= 10) and 66 ± 18% of (S)-[ 18 F]8 (n= 8) DCY, respectively, in over 99% radiochemical purity. Unreacted [ 18 F]fluoride, radiolabeled ionic byproducts as well as hydrogen chloride from the hydrolysis step were removed by passing the reaction mixture through an ion-retardation resin column followed by an alumina N Sep-Pak ® . Less polar and organic byproducts were removed by using a HLB Oasis reverse phase cartridge. While the specific activities of (R)-and (S)-[ 18 F]5 and (R)-and (S)-[ 18 F]8 were not determined directly, the maximum amount of unlabeled material in the final product arising from the precursors is about 1 mg in each case. Based on a 150 mCi yield at EOS, the amount of nonradioactive material in the final dose arising from the precursor is approximately 7 μg per mCi. This amount is comparable to the amount of non-radioactive material present in doses of [ 18 F]FDG which arises from the triflate precursor. 32 Similarly, the non-natural amino acid anti-[ 18 F]FACBC contains non-radioactive material arising from its triflate precursor. 31 
Cell uptake assays
Amino acids enter normal and neoplastic cells through carrier-mediated uptake from the extracellular fluid. For radiolabeled amino acids, tumor uptake is primarily determined by amino acid transport rather than protein synthesis. 5, 6 The most abundant amino acid transport systems in most mammalian cells are system A, system L, system ASC and system Gly. 6, 12, [33] [34] [35] [36] [37] All of these transport systems are sodium-dependent except system L. Prior studies demonstrate that AIB and its analogues including MeAIB, (R,S)-[ 18 F]5 and (R,S)-[ 18 F]8 enter cells mainly through system A transport. 20 ,, 22 To determine the transport mechanisms involved in the uptake of (S)-and (R)-[ 18 F]5 and (S)-and (R)-[ 18 F]8 by 9L gliosarcoma tumor cells, inhibition assays were performed using cultured rat 9L gliosarcoma cells in the presence and absence of amino acid carrier inhibitors. MeAIB is a selective competitive inhibitor of system A transport, and 2-amino-bicyclo[2.2.1]heptane-2-carboxylic acid (BCH) is an inhibitor of system L transport although it is not entirely selective for system L in the presence of sodium. 35, 38, 39 The combination of 10 mM alanine-cysteine-serine (ACS, 3.3 mM of each amino acid) was also used for uptake inhibition as these amino acids are substrates for system ASC. The uptake data was normalized and expressed as mean percent uptake relative to the control condition (Table 1) . In all cases, ACS inhibited more than half of the uptake compared to control (58.2-90.0%). In the case of (R)-and (S)-[ 18 F]5, both BCH and MeAIB inhibited uptake to certain degrees, with 67-75% inhibition by BCH, and 31-58% by MeAIB. In the case of (R)-and (S)- Tumor uptake of (R)-[ 18 F]8 was accumulated from 1.5 to 2.8 %ID/g over the time course of 120 minutes. Tumor uptake of (S)-8 was lower and stable around 1.5 %ID/g under the same conditions. The brain uptake ranged from 0.02 to 0.06 %ID/g at all time points for both [ 18 These results in 9L gliosarcoma tumors showed that the activity accumulated to high levels in the tumors by 30 minutes and stayed at similar high levels through the 120 minutes study course for all four amino acids. The tumor uptake of these four compounds in 9L tumor-bearing rats is depicted in Figure 2 . Statistically significant differences in tumor uptake were observed between the four amino acids in the biodistribution studies: (R)- The high tumor to brain ratios observed with these amino acids was in part due to the low normal brain uptake as well. The normal brain uptake of these four compounds in 9L tumorbearing rats is presented in Figure 3 . There were statistically significant differences in the levels of normal brain uptake for these amino acids at the following time points (p < 0.04 in all cases): (R)- 22 The in vitro inhibition of uptake of these compounds by BCH indicates non-system A transport and is compatible with a component of system L transport. Because system L transport occurs across the normal BBB, substrates for system L would be expected to show uptake in normal brain. The in vitro assay conditions were performed in the absence of amino acids, and it is possible that endogenous system L substrates competitively inhibit the transport of (R)-and (S)- For all four compounds studied, the tumor to brain ratios are higher than those reported for [ 18 Table 3 and Table 4 . The organs which received highest radioactivity were kidneys and pancreas (p<0.0001 compared to other tissues studied), with (S)-[ 18 F]5 higher than (R)-[ 18 F]5 at all time points. The activity in these tissues remained above the activity in other tissues (p≤0.0003 at all time points). For (R)-[ 18 F] 5, the radioactivity uptake in kidneys and pancreas were 3.5 and 3.0 %ID/g at 30 min post injection, respectively, which decreased to 2.1 and 1.2 %ID/g at 120 min post injection, respectively. In the case of (S)-[ 18 F]5, the uptake of activity in these tissues were 8.7 and 3.8 %ID/g at 30 minutes post injection, respectively, which decreased to 6.9 and 2.8 %ID/g at 120 minutes post injection, respectively. With both enantiomers of [ 18 F]5, the tissues studied including blood, liver, heart, lung, spleen, bone, muscle, and testis showed relatively low uptake of radioactivity at 30 minutes (≤0.73% ID/g) which decreased over the course of the two hour study. The brain showed the lowest uptake of radioactivity for both enantiomers of [ 18 F]5 with less than 0.1 %ID/g at all time points (p≤0.0001 compared to other tissues studied). Table 5 and  Table 6 . For both enantiomers of [ 18 F]8, the highest radioactivity uptake occurred in kidneys (p<0.0001 compared to other tissues studied), which decreased through the course of study from 9.2 %ID/g at 15 minutes post injection to 2.5%ID/g at 120 minutes post injection for (R)-[ 18 F]8 and from 11.6%ID/g at 15 minutes post injection to 2.2%ID/g at 120 minutes post injection for (S)-[ 18 F]8. The second highest radioactivity uptake was found in the pancreas (p<0.0001 compared to other tissues studied), which stayed at the same level through the time course of the study with the average value of 2.9 and 3.8%ID/g for (R) 8 showed relatively low uptake in the other organs and tissues, and the lowest activity uptake in brain of less than 0.07 %ID/g at all time points (p<0.0001 compared to other tissues studied).
The high pancreatic and renal uptake in rodent models has been reported for numerous radiolabeled amino acids including substrates for system L and system A. [21] [22] [23] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] The lack of significant accumulation of radioactivity in bone indicates that significant in vivo defluorination resulting from metabolism did not occur with either of these compounds during the two hour studies. Overall, the (R)-enantiomers of 5 and 8 have better imaging properties in the 9L model than the corresponding (S)-enantiomers with lower uptake in the kidneys and pancreas. This difference may be due to the similarity of the α-carbon stereochemistry of (R)- 
Conclusions
The current study demonstrates that (R)-and (S)-[ 18 F]5 and (R)-and (S)-[ 18 F]8 can be produced in high radiochemical yield (> 52% DCY) and high radiochemical purity from stable precursors using a semi-automated synthesis system. Additionally, a new synthetic strategy provides a more efficient route to enantiomerically pure radiolabeling precursors. We found that the stereochemistry influenced the uptake of these compounds by 9L gliosarcoma cells. The inhibition experiments showed that (R)-and (S)-[ 18 
Experimental section
Materials and instrumentation
All chemicals used were obtained from commercially available sources, were of analytical or higher grade and were used without further purification. Solvents used in reactions and purifications were purchased from Aldrich Chemicals Co. (Milwaukee, WI USA) and from VWR Scientific Products (West Chester, PA USA). Thin-layer chromatography (TLC) analyses were performed with 250 μm thick layers of fluorescence UV254 silica gel backing on aluminum plates purchased from Whatman Ltd.(Maidstone, Kent, England). Flash chromatography was carried out using Merck Kieselgel silica gel 60 (230-400 mesh). Melting points were measured in capillary tubes using a Mel-Temp II apparatus (Laboratory Devices, Inc., Holliston, MA USA) and are uncorrected. 1 H NMR spectra were recorded on Varian 600 MHz, 400 MHz or 300 MHz spectrometers at NMR Center in Emory University and chemical shifts (δ values) were reported as parts per million (ppm) downfield from tetramethylsilane (TMS). Elemental analyses were performed by Atlantic Microlabs, Inc. (Norcross, GA USA) and were within ± 0.4 % of the theoretical values unless otherwise indicated. A few of the products were oils which contained trace amounts of solvents and were characterized by high resolution mass spectrometry in conjunction with NMR and TLC to confirm identity. In each and every case, the purity of the identified compound was greater than 95%. Mass spectrometry was performed with a JEOL JMS-SX102/SX102A/E or VG 70-S double focusing mass spectrometers at the Mass Spectrometry Center at Emory University using high resolution electrospray ionization (ESI). Observed masses were within 9 ppm of calculated values.
The [ 18 F]fluoride used for radiosyntheses was produced at Emory University with a 11 MeV Siemens RDS 112 negative-ion cyclotron (Knoxville, TN USA) by the 18 O (p,n) 18 F reaction using [ 18 O]H 2 O (95%). Trap/release cartridges model DW-TRC were purchased from D&W, Inc. (Oakdale, TN, USA). Alumina N SepPak and HLB Oasis reverse phase cartridge were purchased from Waters, Inc. (Milford, MA USA). Ion-retardation resin (AG 11A8 50-100 mesh) was purchased from BioRad (Hercules, CA USA). The 0.2 μm Gelman teflon filters were purchased from VWR. Isolated radiochemical yields were determined using a dosecalibrator (Capintec CRC-712M). Thin layer chromatograms of the radiolabeled compounds were analyzed with a Raytest System (model: Rita Star, Germany) using the same type of TLC plates from Whatman.
All animal experiments were carried out under humane conditions and were approved by the Institutional Animal Use and Care Committee (IUCAC) and Radiation Safety Committees at Emory University. acid (1)-(S)-(+)-2-amino-2-methyl-3-hydroxy- propanoic acid, or (R)-(−)-2-amino-2-methyl-3-hydroxy-propanoic acid [(S)-or (R)-α-methyl-serine] (773 mg, 6.48 mmol, Acros Organics, Morris Plains, NJ, USA) was suspended in 20 mL methanol-triethylamine-1N sodium hydroxide (9:1:1 v/v/v) and di-tert-butyl dicarbonate (2828 mg, 12.96 mmol) was added in one portion. The reaction was stirred at room temperature overnight. The organic solvent was removed under reduced pressure and 10 mL of ethyl acetate was added. The pH of the aqueous phase was adjusted to 2 with 3N hydrochloric acid. The organic layer was retained while the aqueous layer was saturated with sodium chloride and extracted with ethyl acetate (3×10mL). The combined organic phases were dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure. The product (S) or (R)-1 was given as white solid, which were used without further purification. 3-(tert-butoxycarbonyl)-4-methyl-1,2,3 -oxathiazolidine-4-carboxylic acid tert-butyl ester 2-oxide (3)-To a solution of thionyl chloride (297 mg, 2.5 mmol) in 4 mL of anhydrous acetonitrile cooled to −40 °C was added the amino alcohol (S) or (R)-2 (275 mg, 1.0 mmol) in 1 mL of anhydrous acetonitrile under an argon atmosphere followed by the addition of pyridine (396 mg, 5 mmol). After 15 minutes the cold bath was removed, and the reaction was continued for 10 minutes. The solvent was removed under reduced pressure. The crude product was subjected to silica gel column chromatography (20% ethyl acetate in hexane) to afford a ~1.2:1 mixture of cyclic sulfamidite diastereomers (S)-or (R)-3 as colorless oil. The purified mixture of sulfamidite diastereomers was used in the next step reaction without separation. (S)-3-(tert-butoxycarbonyl)-4-methyl-1,2,3-oxathiazolidine-4-carboxylic acid tert-butyl ester 2-oxide ((S)-3) , 306 mg (95.3%), 1 H NMR (CDCl 3 ) for major diastereomer: δ 1.49 (9H, s), 1.54 (9H, s), 1.59 (3H, s), 4.57 (1H, d, J=8 and (R)-3-(tert-butoxycarbonyl)-4-methyl-1,2,3-oxathiazolidine-4-carboxylic  acid tert-butyl ester 2,2-dioxide (4)-A 4-methyl-1,2,3-oxathiazolidine-4 -carboxylic acid tert-butyl ester 2,2-dioxide (6)-To a solution of (S)-or (R)-4 (161 mg, 0.478 mmol) in 2 mL of tert-butyl acetatedichloromethane (4:1 v/v) was added methanesulfonic acid (138 mg, 1.43 mmol) at room temperature under an argon atmosphere. After stirring at room temperature overnight, 5 mL of saturated sodium bicarbonate was added to the mixture. The aqueous phase was extracted with ethyl acetate (3×10mL). The combined organic phases were washed with brine (1×10mL), dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified with silica gel chromatography (20% ethyl acetate in hexane) to give 6 as colorless oil. (S)-4-60 methyl-1,2,3-oxathiazolidine-4-carboxylic acid tert-butyl ester 2,2-dioxide  ((S)-6 ), 64 mg (56.5%). 1 4.69, 4.72 (1H, d, J=9.6 Hz), 5.51 (1H, broad s) . Anal. (C 8 H 15 NO 5 S) C, H, N. (R)-4-methyl-1,2,3-oxathiazolidine-4-carboxylic acid tert-butyl ester 2,2-dioxide ((R)-6 (S)-and (R)-3,4-dimethyl-1,2,3-oxathiazolidine-4-carboxylic acid tert-butyl ester  2,2-dioxide (7) -To a solution of (S)-or (R)-6 (22 mg, 0.093 mmol) in 1 mL of tetrahydrofuran was added sodium hydride (9 mg, 0.37 mmol) at room temperature under an argon atmosphere and the mixture was stirred for 10 minutes after which dimethyl sulfate (47 mg, 0.37 mmol) was added dropwise. The mixture was stirred at room temperature overnight. Water (2 mL) was added and the mixture was extracted with ethyl acetate (2×5mL). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column eluted with 20 % ethyl acetate in hexane to give the title compound as white solid. (S)-3,4-dimethyl-1,2,3-oxathiazolidine-4-carboxylic acid tert-butyl ester 2,2-dioxide ((S)-7 31 The CPCU is a valve-and-tubing system which is designed to accommodate one or two glass reaction vessels and a number of reagent and solvent reservoir containers. The automated production of the 18 F-labeled amino acids was started by delivering 150-200 mCi NCA [ 18 F]HF from cyclotron target through a trap/release cartridge T/R by using 0.9 mg (6.5 μmol) potassium carbonate in 0.6 mL of water to a reaction vial containing 5 mg (13.3 μmol) of kryptofix 222 in 1 mL of acetonitrile. The solvent was removed at 110°C with nitrogen gas flow. Acetonitrile (1 mL) was added and the drying was repeated 3 times to remove residual water. A 1 mg portion of the appropriate cyclic sulfamidate 4 or 7 in 1 mL of acetonitrile was added to the vial, and the reaction mixture was heated at 90 °C for 10 minutes. After acidic hydrolysis using 0.5 mL of 4N hydrochloric acid at 110 °C for 10 minutes, the product was purified 47 by passing serially through an AG 11A8 ion retardation resin column, an alumina N SepPak, an HLB Oasis reverse phase cartridge and a 0.2 μm Gelman teflon filter with sterile normal saline into a dose vial, which was ready for use in vitro and in vivo studies. The identity of the radiolabeled product was confirmed by comparing the R f value of the radioactive product visualized with radiometric TLC with the R f value of the authentic 19 F compound visualized with ninhydrin stain, with a solvent of acetonitrile/ water/methanol = 4:1:1 (v/v/v) (R f = 0.4 for 5, R f = 0.5 for 8). In all radiosyntheses, the only peak present on radiometric TLC analysis corresponded to 5 or 8, and the radiochemical purity of the product exceeded 99%.
Chemistry (S)-and (R)-2-N-(tert-butoxycarbonyl)amino-2-methyl-3-hydroxy-propanoic
(S)-and (R)-2-N-(tert-butoxycarbonyl)amino-2-methyl-3-hydroxy-propanoic acid tert-butyl ester (2)-To a suspension of (S)-or (R)
-
(S)-and (R)-
Amino acid uptake and inhibition assays
These assays were performed by a modified reported method, 22, 38 and the procedures are summarized here. The 9L rat gliosarcoma cell line was cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum, 100 units/mL penicillin and 100ug/mL streptomycin. Cells were maintained in T-150 tissue culture flasks under humidified incubator conditions (37 °C, 5% CO 2 /95% air) and were routinely passaged at confluence. For the cell uptake experiment, 9L cells were dispersed with a 0.05% solution of Trypsin/ethylenediaminetetraacetic acid (EDTA), washed with Hank's balanced salt solution (HBSS) twice and were adjusted to a final concentration of 5×10 7 cells/mL in HBSS.
In this study, approximately 5×10 5 cells were exposed to 5 μCi (R)- After incubation, cells were twice centrifuged (75 G for 5 minutes) and rinsed with ice-cold aminoacid/serum-free HBSS to remove residual activity in the supernatant. The activity in tubes was counted in a Packard Cobra II Auto-Gamma counter, the raw counts decay corrected, and the activity per cell number determined. The data from these studies (expressed and normalized as percent uptake relative to control per 5×10 5 cells) were graphed using Excel, with statistical comparisons using 1-way ANOVA with ProStat software (Poly Software International, Pearl River, NY) between the groups analyzed.
Tumor induction and animal preparation
Rat 9L gliosarcoma cells for intracranial implantation experiments were cultured and prepared the same way as the uptake and inhibition assays, and then were washed with phosphate buffer solution (PBS) and were made a final concentration of 5×10 4 /5ul in PBS. Rat 9L gliosarcoma cells were implanted into the brains of male Fischer 344 rats (200-250 g) as described previously. 19, 22, 38 Briefly, following anesthesia with an intramuscular injection of ketamine (60 mg/mL) and xylazine (7.5 mg/mL) solution, rats were placed in a stereotactic head holder and were injected with 5 μl suspension of rat 9L gliosarcoma cells (5×10 4 cells per rat) in a location 3 mm right of midline and 1 mm anterior to the bregma at 4 mm deep to the outer table. The injection was performed over the course of 2 minutes, and the needle was withdrawn over the course of 1 minute to minimize the backflow of tumor cells. The burr hole and scalp incision were closed, and the animals were returned to their original cages after recovering from the procedure. Intracranial tumors developed that produced weight loss, apathy and hunched posture in the tumor-bearing rats. Typically, among 25 animals implanted with tumor cells, 20 would develop tumors visible to the naked eye upon dissection in approximately 10-12 days and were used in the study.
Rodent biodistribution studies
The tissue distribution of radioactivity was measured in 16-20 tumor-bearing rats, which had been implanted with 9L cells for 10-12 days and were allowed food and water ad libitum before the experiment. The rats were anesthetized using a mixture of 2:1 ketamine (100 mg/ml): xylazine (20 mg/ml). Dose of anesthesia was 0.16 ml/100 grams of rat. This provided 1.5 -2 hours of anesthesia for purpose of catheter placement and injection of radiotracer compound. Euthanasia was achieved by injection of a saturated solution of potassium chloride into the heart of animals while under anesthesia. The animals were dissected; tumors and selected tissues were weighed and the activity counted along with dose standards in a Packard Cobra II Auto-Gamma Counter. The raw counts were decay corrected, and the counts were normalized as the percent of total injected dose per gram of tissue (%ID/g). The uptake in tumor and normal brain was compared at each time point for the each enantiomer pair using 1-way ANOVA corrected for multiple comparisons with ProStat software. The differences in uptake between normal tissues were compared at each time point for each tracer using 1-way ANOVA with ProStat software. The possible route for deprotection of the Boc group at the presence of the tert-butyl ester. Values are reported as percent uptake of the initial dose per 0.5 million cells (% ID/5×10 5 cells) ± standard deviation (SD) (n=3).
Inhibition is expressed as percent relative to control (%).
p values represent comparisons of uptake with inhibitors to control uptake for each radiotracer using one-way ANOVA tests. 
